A multi-center, open-label, randomized controlled clinical trial study on the treatment of Delta novel coronavirus pneumonia (COVID-19) based on ''three-party'' syndrome differentiation and treatment
- Conditions
- Delta Novel Coronavirus Pneumonia
- Registration Number
- ITMCTR2100005149
- Lead Sponsor
- Affiliated Hospital of Nanjing University of Chinese Medicine (Jiangsu Province Hospital of Chinese Medicine)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients with mild and common new coronavirus pneumonia who meet the diagnostic criteria of the ''New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 8)'', with onset within 7 days.
2. Informed consent, volunteer experiment.
3. The process of obtaining informed consent should comply with GCP regulations.
1. Aged <18 years;
2. Combined with serious primary heart, lung, liver, kidney, blood or diseases affecting their survival;
3. Creatinine and ALT/AST exceed 1.5 times the upper limit of normal;
4. Patients with mental illness, limited cognitive ability and disabled patients prescribed by law;
5. Pregnant or lactating patients;
6. Patients within 3 months or participating in clinical trials of other drugs.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 10 day rate of mild and general type conversed to severe type;
- Secondary Outcome Measures
Name Time Method